Drug Trial Radar · NCT02629874
PK/PD of EA-230 During Endotoxemia
Last checked: Nov 19, 2026Latest source record: Jun 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Feb 2015
Primary completion
Jul 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Exponential Biotherapies Inc.
- First posted
- Dec 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
EA-230 is a newly developed synthetic compound with anti-inflammatory properties. Pre-clinical data indicate that EA-230 may be a valuable treatment for systemic inflammation resulting from a variety of causes such as surgery, trauma, infection, irradiation and others. Although previous studies in healthy volunteers have shown an excellent safety profile, the safety and tolerability of higher doses administered per continuous infusion need to be investigated. Also, the dose-effect relation on systemic inflammation needs to be further elucidated before a phase II trial in patients can be commenced.
Conditions
- Endotoxemia
- Systemic Inflammatory Response
Interventions
EA-230Drug
at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
EndotoxinDrug
at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability expressed in treatment related (serious) adverse eventsTime frame: total (S)AE's at day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Intensive care, research unit, Radboud University Medical Centre
Nijmegen, Gelderland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.